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Patients in Hawaii 
Alan H.S. Cheung MD, Whitney M.L. Limm MD, Linda L. Wong MD 
Diabetes mellitus is a common disease affecting a large popu-
lation in Hawaii. Over the past 20 years, pancreas transplanta-
tion has evolved into a viable therapeutic option for selected 
patients with diabetes mellitus. This report describes the first 
combined pancreas-kidney transplant performed in Hawaii on 
June 28, 1993 on a patient with juvenile-onset diabetes mellitus 
and diabetic nephropathy. The patient has remained off insulin 
and off dialysis since the transplant. The history, indications, 
techniques, and potential complications related to this proce-
dure are discussed. 
Case 1 
The patient was a 38-year old woman from Maui who 
developed signs and symptoms of diabetes mellitus when she 
was 5 years old. Insulin was recommended at that time but her 
family refused. She was started on an oral agent, tolbutamide 
( Orinase®) in the 1980s. In 1986, she was started on insulin, and 
prior to surgery was administering 15 units of Humulin in 
morning and 5 units in the evening. On this schedule, her blood 
sugar ranged between 70 and 250 mg/dl on any given day. She 
had no history of seizures, coma or diabetic ketoacidosis, but 
developed progressive diabetic triopathy, including diabetic 
nephropathy, retinopathy, and neuropathy. She was started on 
hemodialysis on July 29, 1991. She had progressive retinopathy 
and has had bilateral laser photocoagulations as recently as 
March 1992. She had numbness and parasthesia of both lower 
extremities secondary to neuropathy; her other medical prob-
lems included a left heel ulcer, hypertension, and a history of 
asthma. 
As part of her evaluation for a possible pancreas and kidney 
transplant, the patient underwent extensive ophthalmologic and 
cardiac evaluations, including a coronary angiogram; the results 
were normal. A duplex scan of the lower extremities revealed no 
evidence of significant atherosclerosis. Her creatinine level was 
10.6 mg/dl and her hemoglobin A1C was 12% (normal range is 
5.5% to 7.7% ). She was deemed to be a good candidate, and was 
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placed on the waiting list for a combined kidney/pancreas 
transplant on December 1992. 
An 18-year old donor, who died of a severe intracerebral 
injury following a skateboard accident, was pronounced brain 
dead and consent was given for multiple organ procurement. 
The donor had a creatinine of0.8 mg/dl, and normal glucose and 
amylase levels. 
Our patient was hospitalized on the evening of June 27, 1993 
and was found to have a serum glucose of 255 mg/dl. She was 
started on an intravenous insulin drip at 2 units an hour. Her 
BUN and creatinine levels on admission were 93 mg/dl and 10.6 
mg/dl, respectively. 
A combined cadaveric kidney and pancreas transplant was 
performed on June 28, 1993. The operation took approximately 
7 hours: A midline incision was made and the kidney was placed 
intraperitoneally in the left iliac fossa, the renal artery and vein 
were anastomosed to the patient's left iliac artery and vein, 
respectively. The kidney graft functioned immediately, produc-
ing urine while the patient was still on the operating room table. 
The pancreas graft was reconstructed on the back table, since the 
liver was also procured. The donor splenic artery and superior 
mesenteric artery were reconstructed, using a Y -graft of donor 
iliac arteries. This Y -graft was then anastomosed to the patient's 
right common iliac artery; the donor portal vein was anasto-
mosed to the patient's right external iliac vein; a segment of 
donor duodenum was left intact and was anastomosed to the 
urinary bladder (Fig 1 ). The ureter was then anastomosed using 
the posterior Leadbetter-Politano method. 
Postoperatively, the patient was taken to the intensive care 
unit where she was continued on an insulin drip; her serum 
glucose had dropped immediately to 86 mg/dl. Intravenous 
insulin was continued for the first few days in order to maintain 
tight control of the serum glucose between 100 to 150 mg/dl. The 
insulin drip was stopped by post -operative day 5 and the patient's 
blood sugar remained stable while off insulin, ranging between 
109 mg/dl to 150mg/dl. (Fig2). Immunosuppression was begun 
with ATGAM® for 10 days, followed prednisone, azathioprine, 
and cyclosporine A. Antibiotic prophylaxis was given with 
vancomycin and irnipenem (Primaxin®) for3 days. Fluconazole 
was given for 14 days, and CMV prophylaxis was instituted with 
ganciclovir for 10 days, followed by acyclovir for 3 months. The 
patient was discharged 17 days after the transplant, with a serum 
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amylase of94 IUn, serum glucose of 110 mg/dl without insulin, 
and a creatinine of 0.9 mg/dl. 
The 6-month follow-up indicates the patient remains off 
dialysis and insulin. Her most recent serum creatinine was 1.1 
mg/dl, and her blood sugar was 96 mg/dl. Her hemoglobin A1 C 
level at 3 months was down to 8.0% (normal5.5% to 7. 7% ). The 
patient did have an episode of acute rejection of both the 
pancreas and the kidney which was successfully reversed with 
OKT3®. She had complications related to her steroid immuno-
suppression, including CMV infection, and a duodenal anasto-
motic leak, which was successfully repaired. The patient is now 
at home on Maui. 
Discussion 
According to the local American Diabetes Association, diabe-
tes mellitus affects about 78,000 residents of Hawaii. Since the 
discovery of insulin, Type 1 diabetes mellitus has been trans-
formed from a lethal disease to a chronic illness, with many 
patients going on to develop secondary systemic complications. 
Since constant euglycemia is unachievable for diabetic patients 
by any practical mode of exogenous insulin administration, and 
since hypoglycemia is intolerable, chronic hyperglycemia (as 
documented by measurements of glycosylatedhemoglobin) is the 
usual state in these patients.1 After years of debate, the Diabetic 
Control and Complications Trial (DCCT) has now unequivocally 
shown that the development of neuropathy and retinopathy is 
related to the degree to which hyperglycemia is controlled.2 
Complications affecting the eyes, nerves and kidneys are present 
in more than 50% of patients who survive more than 20 years with 
diabetes. Even today, the average life span of people with diabetes 
is significantly shorter than that of the general population. 1 
As the DCCT study indicates, 2 only perfect glucose control for 
diabetic patients can prevent diabetic complications, but a perfect 
insulin delivery system has not been developed. An alternative to 
insulin injection is pancreas transplantation. It was originally 
thought that since diabetes is caused by insufficient production of 
insulin by the beta cells in the islets ofLangerhans, transplanting 
these insulin-producing cells would allow perfect control of 
blood glucose. 
The modem history of clinical pancreas transplantation was 
started on December 16, 1966, when the first human pancreas 
transplant was performed by Drs Kelly, Lillehei and associates at 
the University of Minnesota. 1•3 This case involved a uremic 
diabetic recipient on dialysis who had a simultaneous pancreas-
kidney transplant. Since the initial transplant 27 years ago, more 
than 1,500 pancreases have been transplanted worldwide. The 
technique has evolved such that the 1-year patient survival is in 
excess of 90%, and the 1-year pancreas graft survival is appro xi-
mately 85%.3 This is comparable to results attained in kidney and 
other solid organ transplants. Furthermore, successful pancreas 
transplants have been shown to stabilize or improve neuropathy 
and prevent recurrence of diabetic nephropathy in kidney grafts. 
Diabetes mellitus 
Diabetes mellitus (Type 1 and Type 2) affects approximately 
5% of the U.S. population. It is the leading cause of blindness 
-
each year. Compared with the normal population, patients with 
diabetes have a 25-fold increase in blindness, a 17 -fold increase 
in risks of renal disease, a 25-fold increase risk of peripheral 
gangrene and a 2-fold increase in risk of heart disease and 
strokes3• Furthermore, diabetes accounts for 80% of major non-
traumatic amputations each year. The late complications of 
diabetes include macroangiopathy, microangiopathy, 
retinopathy, nephropathy, cardiomyopathy, and neuropathy. 
Since the life expectancy of most diabetic patients is shorter than 
that of the normal population, the goals of the pancreas trans-
plant are: 1) To maintain near normal glucose metabolism; 2) to 
improve the quality oflife for these patients; and 3) to avoid the 
late complications and higher mortality. In 1990, more than 600 
pancreas transplants had been performed worldwide. 
Recipient selection 
Unlike the heart or liver transplant, which are life-sustaining 
organs, the pancreas is non-vital in that exocrine and endocrine 
replacements currently are available. Therefore, the justifica-
tion of the risk of surgery and life-long immunosuppression 
cannot be taken lightly. There are 3 categories of patients who 
could benefit from the pancreas transplant (Table 1). 
The first are patients with end-stage diabetic nephropathy 
who are on dialysis. Many of these patients wantto have a kidney 
transplant for an improved quality of life by being off dialysis. 
Since they will undergo surgery for the kidney transplant and 
will require life-long immunosuppression, performing a com-
bined kidney and pancreas transplant in this group would not 
increase the surgical or immunosuppressive risks significantly. 
Our patient was in this category. Patients who have had a 
successful kidney transplant could ask to be candidates for a 
pancreas transplant, since they are already on life-long immuno-
suppression. The only disadvantage is that they will have to 
undergo a second operation for the pancreas transplant. 4•5 
The second category is patients with pre-uremic diabetic 
nephropathy who have documented macro-albuminuria. The 
natural history in this group of patients is that they will ulti-
mately require dialysis. Performing the pancreas transplant 
alone may prevent the diabetic damages to the kidney and 
ultimately avoid dialysis in these patients. 
The final category is patients with severe diabetic manage-
ment problems. These patients have hyperlabile diabetes or 
special problems associated with unawareness ofhypoglycemia. 
Some of these patients have a profoundly poor quality of life 
with seizures and comas, and many of them are afraid to leave 
their homes. For these patients, a pancreas transplant alone 
could cure their diabetes and improve their quality of life. 6 
The detailed clinical criteria for candidates for pancreas 
transplantation or combined kidney/pancreas transplantation 
are listed in Table 2. Besides active infections or malignancies, 
other contraindications for pancreas transplantation are listed in 
Table 3. 
Donor selection 
Almost all transplant centers now rely exclusively on cadaver 
donors for their pancreas organs. The cadaveric donor should 
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Table 1 Possible indications for pancreas 
transplantation in diabetic patients 
Patient's condition 
End-stage diabetic nephropathy 
Pre-uremic diabetic nephropathy 
Severe management problems: 
• Hyperlabile diabetes 
• Unawareness of hypoglycemia 
• Severe neuropathic pain 
Type of transplantation 
Combined kidney and 
pancreas transplant, 
or pancreas after 
kidney transplant 
Pancreas transplant alone 
Pancreas transplant alone 
Table 2 Clinical criteria for candidates 
for pancreas transplantation or combined 
kidney/pancreas transplantation 
1. Adults, ages 18 to 50 years 
2. Presence of insulin-dependent diabetes 
3. Well-controlled blood pressure, with or without medication 
4. No evidence of inoperable peripheral vascular disease-specifically, 
cerebrovascular disease or ischemic ulcers-or previous 
amputation necessitated by vascular disease 
5. Not requiring narcotics or large amounts of analgesics 
6. No recent retinal hemorrhage 
7. No history of major or significant myocardial infarction 
8. No insulin resistance-that is, insulin requirement of no more 
than 2u/kg. 
9. No other contraindications to transplantation, including previous 
multiple operations, active infections, or malignant lesions 
1 0. Ability to understand risks and benefits of the procedure and to 
cooperate and comply with the medical program 
Table 3 Contraindications for pancreas 
transplant 
• Ongoing peripheral gangrene 
• Severe coronary insufficiency with angina or intractable cardiac 
decompensation 
• Severely incapacitating peripheral neuropathy, ie, bedridden 
patients 
• Severely incapacitating autonomic neuropathy, ie, gastroparesis 
have no history of diabetes mellitus. Other absolute contra-
indications include severe chronic pancreatitis and a history of 
pancreatic damage by trauma. Relative contraindications in-
clude alcoholism, recurring acute pancreatitis, and elevated 
levels of blood glucose or serum amylase levels. The usual 
-
criteria for organ donation are noted in this issue in Dr Whitney 
Limm's article, "The Need for Organ Donation in Hawaii". 
Operative technique 
The procedure of pancreas transplantation has evolved to the 
current technique of transplanting the whole pancreas organ 
with a segment of duodenum for exocrine drainage into the 
urinary bladder (Fig 1 ). This approach allows external drainage 
of the pancreatic duct without the contamination involved with 
an enteric anastomosis. This also provides the opportunity to 
monitorurinepHandamylaseasameasureofpancreasallograft 
function and to biopsy the pancreas if necessary via cystoscopy. 7•8 
Immunosuppression, rejection, and 
complications 
The extensive experience at the University of Minnesota has 
suggested that a triple therapy of maintenance immunosuppres-
sion using cyclosporine, azathioprine, and prednisone in combi-
nation has the highest success rate. Antilymphocyte globulin, 
such as ATGAM®, usually is given in the immediate post-
operative period. 
Rejection of the pancreas allograft is mainly manifested in the 
deterioration of graft function; inflammatory signs may occur, 
although inconsistently. A gradual, progressive hyperglycemia 
with presumed etiology secondary to rejection may be noted. A 
decrease in urinary amylase output during rejection episodes 
may occur up to 4 days prior to clinical hyperglycemia. Urinary 
amy lase has proven to be a sensitive indicator of early rejection; 
early treatment of rejection decreases graft loss. Furthermore, 
cystoscopically directed biopsy of the pancreas can confirm 
early rejection. Serum anodol trypsinogen also has been shown 
to be a marker for early acute rejection. Even with the triple 
therapy, rejection can occur in 50% to 70% of the cases,' as 
occurred in our patient. Fortunately, rejection can be reversed in 
over 95% of the cases by using OKT3® a monoclonal antibody 
directed against T -lymphocytes. 
Surgical complications occur in 30% to 40% of cases: 
hyperamylacemia, graft pancreatitis, pancreatic pseudocysts 
and ascites, pancreatic fistula, anastomotic leaks with fistula, 
intra-abdominal abscess, graft thrombosis, bleeding, intestinal 
obstruction or perforation. Opportunistic infections and poten-
tial malignancies also can occur, as in any immunosuppressed 
patient. 
Results 
After a successful pancreas transplant, blood glucose normal-
izes within hours or days. Patients can maintain a normal or near 
normal fasting blood glucose and half develop normal 
glycosylated hemoglobin levels. Both were shown in our pa-
tient. Most individuals have a normal oral and intravenous 
glucose tolerance test. A successful pancreas transplant can 
prevent the occurrence of diabetic nephropathy or the progres-
sion of early diabetic lesions in grafts exposed to the diabetic 
milieu. Depending on the stage of the ophthalmic lesions, the 
probability of advanced retinopathy progression is not altered in 
the first few years after a pancreas transplant. However, the 
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Fig 1.-Technique of combined pancreas-kidney transplantation with the 
duodenal segment technique. The kidney is placed in the left iliac fossa, and the 
pancreas in the right. The duodenum is drained into the bladder 
(Courtesy of WB Saunders Company.)" 
retinopathy stabilizes after 3 years with a successful pancreas 
transplant. Neuropathy improves or stabilizes for most recipi-
ents. The nerve conduction velocity and evoked muscle action 
potentials increase. Patients with severe autonomic neuropathy 
have a significantly higher probability of survival than patients 
who did not undergo transplant. 
Many studies have looked at the influence of a successful 
pancreas transplant on the quality of life and the effects of day-
to-day living in these patients. The quality of life for many 
individuals improves simply with insulin independence. Ninety-
two percent of patients thought that managing immunosuppres-
sion was easier than managing diabetes and insulin. 9 About two-
thirds thought that diabetes was more demanding on their 
families ' time and energy than the transplant.9 All of the patients 
with successful graft function said they would encourage others 
with similar diabetic problems to consider a pancreas trans-
plant.10 Interestingly, even most of the patients with a failed 
pancreas graft opted for re-transplantation, and most with func-
tioning grafts said that they would undergo a re-transplant if 
their current graft failed. 10 Since pancreas transplantation is a 
complicated procedure, it is natural to question whether the 
benefit is worth the price, and many pancreas transplant recipi-
ents have emphatically stated that it is. 
The one year pancreas allograft survival rate is over 70% to 
85% in diabetic recipients of a simultaneous kidney and pan-
creas transplant.3•8 The one-year patient-survival rate is over 
90%. This is similar to those achieved with other solid organ 
transplants. 
Summary 
Pancreas transplantation as a treatment for diabetes mellitus 
is the youngest area in the growing field of organ transplantation. 
Over the past 26 years, it has evolved into a viable therapeutic 
option for selected patients with diabetes mellitus. Until islet 
transplant or gene therapy for treatment of diabetes becomes a 
-
HAWAII'S ARST PANCREAS TRANSPLANT 
~~o---G-.. L""'l (mo""l 
-e- lnsolin Un~s per Day 
Ftg 2.-The glucose level after our patienrs successful pancreas transplant. 
Insulin was stopped after the 5th post-operative day. 
reality, pancreas transplant remains the only proven cure for 
selected patients with diabetes mellitus in 1994. 
Acknowledgement 
Many individuals have contributed to the care of our first 
pancreas/kidney transplant patient. Special thanks go to Drs 
Steve Moser and Gregory Park for the referral of this patient, and 
Dr Jared Sugihara for his excellent care and assistance. 
References 
1. Sutherland DFR, Gores PF, Farney AC, et al. Evolution of kidney, pancreas, and islet 
transplantation for patients with·diabetes at the University of Minnesota. The Am J 
Surg . 1993;166:456-491. 
2. The Diabetes Control and Complications Trial research group. The effect of intensive 
treatment of diabetes on the development and progression of long-term complica-
tions in insulin-dependent diabetes mellitus. N Eng/ J Med. 1993;329:9n-986. 
3. Cheung AHS. Pancreas transplantation. Resident and Staff Physician. 1991 ;37: 55-
58. 
4. Cheung AHS, Sutherland DER, Gillingham KJ, et al. Simultaneous pancreas-kidney 
(SPK) transplant versus kidney transplant alone (KT A) in diabetic patients. Kidney 
lnt 1992;41 :924-929. 
5. Cheung AHS, Matas AJ, Gruessner RWG, et al. Should uremic diabetic patients who 
want a pancreas transplant receive a simultaneous cadaver kidney-pancreas trans-
plant or a living-related donor kidney first followed by cadaver pancreas transplant? 
Transplant Proc. 1993;25:1184-1185. 
6. Velosa JA, Frohnert PP, Perkins JD, et al. Pancreas transplantation at Mayo: I. 
Patient selection. Mayo C/in Proc. 1990;65:475-482. 
7. Perkins JD, Fromme GA, Narr BJ, et al. Pancreas transplantation at Mayo: II. 
Operative and perioperative management. Mayo Clin Proc. 1990;65:483-495. 
8. Perkins JD, Frohnert PP, Service FJ, et al. Pancreas transplantation at Mayo: Ill. 
Multidisciplinary management. Mayo Clin Proc. 1990;65:496-508. 
9. Voruganti LNP, Sells RA. Quality of life of diabetic patientsaftercombined pancreatic-
renal transplantation. C/in Transplantation. 1989;3:78-82. 
10. Nakache R, Tyden G, Groth CG. Quality of life in diabetic patients after combined 
pancreas-kidney or kidney transplantation. Diabetes. 1989;38 (Suppl1):40-42. 
11. Sollinger HW, KnechUe SJ. The current status of combines kidney-pancreas trans-
plantation. In Sokiston DC (Ed.). Textbook of Surgery. 1990;87. 
HAWAII MEDICAL JOURNAL VOL 53, MARCH 1994 
93 
